Subtle Medical Announces Positive Findings from Proof-of-Concept Study with Bayer Investigating AI To Lower Gadolinium Dose in CE-MRI
MENLO PARK, Calif., Oct. 21, 2025 /PRNewswire/ — Subtle Medical, Inc., a leader in AI-powered medical imaging solutions, today announced positive findings from a proof-of-concept (POC) study with Bayer, a leader in Radiology, evaluating Subtle Medical’s investigational SubtleGAD™ technology.
The study, including 39 patients undergoing imaging of the brain, conducted across five leading U.S. sites including Mayo Clinic, MD Anderson Cancer Center, OSF St. Francis Hospital Peoria, University of Massachusetts and The Pennsylvania State University, investigated SubtleGAD™, an AI-enabled algorithm aiming to synthesize full-dose contrast-enhanced images by enhancing contrast signals in MRI using a reduced contrast agent dose, with the goal to generate diagnostic-quality images.
In the study, patients received one of two investigational reduced doses of a gadolinium-based contrast agent after an initial full-dose baseline exam. Using Subtle Medical’s deep learning algorithm, synthesized full dose MR images from the reduced-dose acquisitions were compared with the standard-dose images.
Findings suggested similarity of the investigational AI-synthesized reduced-dose images when comparing lesion visualization parameter scores—contrast enhancement, border delineation, and internal morphology—with those of standard full-dose images.
